Companies · Biotechnology

SmartFlow Technologies, Inc.

APEX · Biotechnology

Diligence memoA one-page analyst read on SmartFlow Technologies, Inc. — recommendation, valuation, rhythm, risks.
$8.4M
Total raised · real
5
Rounds
3.4×
Latest step-up
Top 48%
Sector rank · raised
Series A
Latest stage · inferred · Mon Apr 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

SmartFlow Technologies, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.11× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
Dormant
  • Last raise 15.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

SmartFlow Technologies, Inc. is one of 4293 Biotechnology companies tracked from APEX. By capital raised it ranks mid-pack (ahead of 53% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2007-12-28 Raised $2.5M (real) Modeled valuation $111M (est)$2.5M$111MSeed2007Series A · 2009-11-03 Raised $4.4M (real) Modeled valuation $158M (est)$4.4M$158MSeries A2009Series A · 2010-07-13 Raised $800K (real) Modeled valuation $29M (est)$800K$29MSeries A2010Series A · 2010-07-13 Raised $175K (real) Modeled valuation $6.3M (est)$175K$6.3MSeries A2010Series A · 2011-04-11 Raised $600K (real) Modeled valuation $22M (est)$600K$22MSeries A2011+$4.4M+$800K+$175K+$600KCumulative $8.4M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.5M · 2007
Series A$4.4M · 2009
Series A extension$800K · 2010
Series A extension$175K · 2010
Series A extension$600K · 2011

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$21.7M
Base estimate est.
$655K
Conservative case
$117.9M
Upside case
$2.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $111.0M · 2007-12-282007Series A · modeled $158.1M · 2009-11-03Series A · modeled $28.9M · 2010-07-13Series A · modeled $6.3M · 2010-07-13Series A · modeled $21.7M · 2011-04-112011
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
15.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
10 mo
Avg between rounds
$2.6M/yr
Capital velocity
18.5 yr
On record since
2007
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.2× above median
This company$8.4M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$600K
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$21.7M
Sector median$64.2M

Raised more than 53% of sector peers (real $). Modeled value above 29% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #88 of 92.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Tobira Therapeutics, Inc. · Series A Raised $23.2M · modeled $513.3M (est)Neoprobe Corp · Series A Raised $14.0M · modeled $506.1M (est)Akebia Therapeutics, Inc. · Series A Raised $25.9M · modeled $504.1M (est)Adimab, LLC · Series A Raised $13.8M · modeled $499.5M (est)Elevation Pharmaceuticals Inc · Series A Raised $27.4M · modeled $448.3M (est)Mnemosyne Pharmaceuticals Inc · Series A Raised $24.0M · modeled $445.8M (est)Macrogenics Inc · Series A Raised $12.0M · modeled $434.4M (est)Neurologica Corp · Series A Raised $17.0M · modeled $433.8M (est)Bodymedia Inc · Series A Raised $20.1M · modeled $429.9M (est)Peloton Therapeutics, Inc. · Series A Raised $13.7M · modeled $423.0M (est)Seahorse Bioscience Inc · Series A Raised $20.7M · modeled $410.2M (est)Stemgent, Inc. · Series A Raised $37.9M · modeled $408.5M (est)SmartFlow Technologies, Inc. (this company) Raised $8.4M · modeled $21.7M (est)SmartFlow Technologies, Inc.
CompanyStageRaised · realValue · estvs peer med.
Tobira Therapeutics, Inc.Series A$23.2M$513.3M2.56×
Neoprobe CorpSeries A$14.0M$506.1M2.53×
Akebia Therapeutics, Inc.Series A$25.9M$504.1M2.52×
Adimab, LLCSeries A$13.8M$499.5M2.50×
Elevation Pharmaceuticals IncSeries A$27.4M$448.3M2.24×
Mnemosyne Pharmaceuticals IncSeries A$24.0M$445.8M2.23×
Macrogenics IncSeries A$12.0M$434.4M2.17×
Neurologica CorpSeries A$17.0M$433.8M2.17×
Bodymedia IncSeries A$20.1M$429.9M2.15×
Peloton Therapeutics, Inc.Series A$13.7M$423.0M2.11×
Seahorse Bioscience IncSeries A$20.7M$410.2M2.05×
Stemgent, Inc.Series A$37.9M$408.5M2.04×
SmartFlow Technologies, Inc. this companySeries A$8.4M$21.7M0.11×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.5M2007-12-28$12.5M$111.0M90%
Series A$4.4M2009-11-03$19.9M$158.1M90%
Series A$800K2010-07-13$3.6M$28.9M90%
Series A$175K2010-07-13$795K$6.3M90%
Series A$600K2011-04-11$2.7M$21.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.5M2007-12-28
    • First recorded raise — entered as Seed.
  2. Series A$4.4M2009-11-03
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
  3. Series A$800K2010-07-13
    • Raised 8 mo later, in step with the ~14 mo sector norm.
    • Round 5.5× smaller than the prior — bridge or down round.
  4. Series A$175K2010-07-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.6× smaller than the prior — bridge or down round.
  5. Series A$600K2011-04-11
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 3.4× larger than the prior — scaling up.
Intelligence
2012 ~Q1
Modeled next raise · ~10mo cadence
$1.8M
Modeled next size est.range $1.2M$2.9M
3.4×
Last step-up
$2.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Jamie M. Grooms3 other2010-07
M. Tatum Pursell2 other2007-12
Walter P. Maner1 other2009-11
Jamie A Grooms2007-12
Kenneth A. Graham2007-12
Kim A. Davis2007-12
Michael B. Morrissey2007-12
Registry & provenance

SmartFlow Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1334620
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
AutoIVF, Inc.BiotechnologySeries A$8.6M$17.4Msame sector · same stage
SkinJect, Inc.BiotechnologySeries A$8.3M$19.6Msame sector · same stage
Grid Therapeutics LLCBiotechnologySeries A$8.2M$19.9Msame sector · same stage
CMI HOLDING Co INCBiotechnologySeries A$8.8M$23.5Msame sector · same stage
Vail Scientific, L.L.C.BiotechnologySeries A$8.1M$27.0Msame sector · same stage
IMMvention Therapeutix, Inc.BiotechnologySeries A$8.9M$21.9Msame sector · same stage
Althera Medical Ltd.BiotechnologySeries A$8.0M$16.0Msame sector · same stage
Halcyon Wellness Inc.BiotechnologySeries A$8.0M$18.9Msame sector · same stage
Frequently asked
How much funding has SmartFlow Technologies, Inc. raised?
SmartFlow Technologies, Inc. has raised approximately $8.4M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is SmartFlow Technologies, Inc.'s estimated valuation?
Provath's modeled valuation for SmartFlow Technologies, Inc. is approximately $21.7M (modeled range $655K–$117.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is SmartFlow Technologies, Inc. at?
SmartFlow Technologies, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Apr 11.
What does SmartFlow Technologies, Inc. do and where is it based?
SmartFlow Technologies, Inc. operates in the Biotechnology sector, based in APEX.
Explore related

See where SmartFlow Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at SmartFlow Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.